Latest News and Press Releases

TEL AVIV, Israel, Nov. 23, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today reported financial results and provided a business update for the third quarter and nine month period ended...

TEL AVIV, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, Oct. 13, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that it has engaged in a long-term lease contract of a new stand-alone facility in Modiin,...

TEL AVIV, Israel, Sept. 06, 2016 (GLOBE NEWSWIRE) -- VBL THERAPEUTICS (NASDAQ:VBLT), today announced it will present at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored...

TEL AVIV, Israel, Aug. 15, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, July 26, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, June 21, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, June 16, 2016 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ:VBLT) announced that on June 10, 2016, it closed its previously...

Dror Harats, CEO will discuss ASCO newly-reported VB-111 clinical data in Ovarian Cancer and rGBM TEL AVIV, Israel, June 07, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced...